article
Belgo-Dutch immunology company argenx saw its shares close down 1.4% at 345.80 euros today, after it revealed that the US Food and Drug Administration (FDA) has extended the review of the Biologics License Application (BLA) for subcutaneous (SC) efgartigimod (1,000mg efgartigimod-PH20) for the treatment of adult patients with generalized myasthenia gravis (gMG) to June 20, 2023. 27 January 2023